Curated News
By: NewsRamp Editorial Staff
September 09, 2026
GeoVax Applauds New Global Mpox Vaccine Stockpile; GEO-MVA Ready for Phase 3
TLDR
- GeoVax's GEO-MVA could secure market share in the new global mpox vaccine stockpile, offering an additional MVA supply source.
- The new stockpile, funded by Gavi and coordinated by ICG, establishes a long-term mechanism for equitable mpox vaccine access.
- This global mpox vaccine stockpile ensures equitable and timely access, improving outbreak response and global health preparedness.
- GeoVax's GEO-MVA progresses toward Phase 3, aiming to add a reliable MVA vaccine source to the new stockpile.
Impact - Why it Matters
The establishment of a global mpox vaccine stockpile marks a critical shift from reactive outbreak control to proactive preparedness, ensuring that vaccines are available equitably and swiftly during future mpox emergencies. For the public, this means reduced risk of severe outbreaks and better protection for vulnerable populations worldwide. For GeoVax, it underscores the importance of diversifying vaccine supply and manufacturing capacity, which is essential for meeting global demand and enhancing biosecurity. The company's progress with GEO-MVA could contribute to a more resilient supply chain, ultimately saving lives and preventing widespread disruption.
Summary
GeoVax Labs, Inc. (Nasdaq: GOVX) has welcomed the launch of a new global mpox vaccine stockpile, an initiative funded by Gavi, the Vaccine Alliance, and coordinated through the International Coordinating Group (ICG) on Vaccine Provision, which includes WHO, UNICEF, MSF, and IFRC. The stockpile, announced on September 2 and operational by the end of September, aims to provide countries with timely, equitable, and sustainable access to mpox vaccines during outbreaks, moving from reactive responses to sustained preparedness.
GeoVax is developing GEO-MVA, an MVA-based vaccine candidate for mpox and smallpox, and has achieved key milestones supporting the planned initiation of a pivotal Phase 3 immune-bridging study in Q4 2026. These include GMP manufacturing readiness, regulatory alignment with the European Medicines Agency (EMA), clinical site identification, and positive preclinical data. The company believes that additional qualified MVA vaccine sources, like GEO-MVA, can expand supply availability and manufacturing capacity, strengthening global preparedness.
Beyond GEO-MVA, GeoVax is advancing next-generation technologies such as MVA-X for single-dose protection, continuous-cell-line manufacturing, and microarray-based delivery to further address barriers to global vaccine access. The company is engaging with government agencies and international organizations to support future procurement and supply flexibility. As the stockpile infrastructure develops, GeoVax's objective is to contribute a reliable additional source of MVA vaccine capacity, aligning with the shared goal of equitable access worldwide.
Source Statement
This curated news summary relied on content distributed by NewMediaWire. Read the original source here, GeoVax Applauds New Global Mpox Vaccine Stockpile; GEO-MVA Ready for Phase 3
